Sajal Dutta, MD
Urology · Portland, ORNPI 1528055548
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.9%), travel and lodging and education — rather than concentrated in one kind of arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 22.8%. Reporting peaked in 2019 at $3,433 and has fallen 84.2% since, to $541 in 2025.
Across 196 payments — averaging $50.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$2K
- Boston Scientific$2K
- Teleflex LLC$2K
- Coloplast$1K
- AbbVie$371
- Pfizer$364
- plus $2K from 31 others
What the payments were for
- Speaking & faculty fees$3504%
- Travel & lodging$3,93540%
- Food & beverage$4,90250%
- Education$6366%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 14 | $2,237 |
| Boston Scientific | 20 | $1,768 |
| Teleflex LLC | 14 | $1,513 |
| Coloplast | 12 | $1,133 |
| AbbVie | 18 | $371 |
| Pfizer | 16 | $364 |
| Bayer | 13 | $329 |
| Dendreon Pharmaceuticals LLC | 12 | $319 |
| Astellas Pharma US Inc | 12 | $239 |
| Sumitomo Pharma America, Inc. | 4 | $184 |
| Johnson & Johnson(2 entities) | 7 | $148 |
| Abbott | 1 | $140 |
| Northgate Technologies, Inc. | 1 | $92 |
| Tolmar, Inc. | 5 | $83 |
| Accord Healthcare, Inc. | 5 | $80 |
| Olympus America Inc. | 3 | $75 |
| Travere Therapeutics, Inc. | 6 | $64 |
| Endo Pharmaceuticals Inc. | 4 | $60 |
| Merck | 3 | $58 |
| Intuitive Surgical | 1 | $54 |
| 180 Medical, Inc. | 2 | $53 |
| Myriad Genetic Laboratories, Inc. | 3 | $49 |
| Ferring Pharmaceuticals Inc. | 3 | $46 |
| LSI Solutions Inc | 1 | $42 |
| Urogen Pharma, Inc. | 2 | $36 |
| AstraZeneca | 1 | $35 |
| Convatec Inc. | 2 | $34 |
| Vertex | 1 | $33 |
| Pharmaessentia USA Corporation | 1 | $26 |
| Amgen | 1 | $25 |
| Agiliti Surgical, Inc. | 1 | $24 |
| Novartis | 1 | $22 |
| Immunitybio, Inc. | 1 | $21 |
| Urovant Sciences Inc | 1 | $17 |
| Valencia Technologies Corporation | 1 | $17 |
| Hollister Incorporated | 1 | $16 |
| Cook Medical LLC | 2 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$3,233
- Lumenis Pulse 120H$1,451
- TITAN$882
- AMPLATZER$140
How this compares
$9,824 in reported general payments places this provider in the 85th percentile of 153 urology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 14 | $209,988 |
| Abiraterone Acetate | 34 | $41,351 |
| GemtesaVibegron | 32 | $37,521 |
| MyrbetriqMirabegron | 46 | $33,455 |
| Tamsulosin Hcl | 298 | $3,981 |
| Finasteride | 255 | $3,397 |
| NitrofurantoinNitrofurantoin Macrocrystal | 62 | $2,755 |
| Tolterodine Tartrate ErTolterodine Tartrate | 25 | $2,446 |
| Solifenacin Succinate | 22 | $2,406 |
| Bicalutamide | 36 | $1,852 |
| Oxybutynin Chloride ErOxybutynin Chloride | 33 | $1,013 |
| Estradiol | 18 | $994 |
| Dutasteride | 17 | $849 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 72 | $698 |
| Cephalexin | 38 | $568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $239 | $243,44360 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $184 | $37,52132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 153 urology providers in Oregon.
Other urology in Portland
- Lance MarrPortland$323K
- da David JiangPortland$65K
- Amir PatelPortland$36K
- James TycastPortland$35K
- Sudhir IsharwalPortland$30K
- Ian MetzlerPortland$23K
- Sara Spettel AliyarPortland$21K
- Daniel JanoffPortland$15K
- James BreseePortland$14K
- Stanley MyersPortland$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.